Meningococcemia

Summary

Meningococcemia (MONDO:0042972) is a disease and 8 clinical trials. A subtype of bacterial infectious disease with sepsis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	meningococcemia
Mondo ID	MONDO:0042972
SNOMED CT	4089001
UMLS	C0025306
MedGen	6300
GARD	0027965
Is cancer (heuristic)	no

Also known as: meningococcemia

Disease family

This is a subtype of bacterial infectious disease with sepsis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial infectious disease with sepsis › meningococcemia

Related subtypes (4): gas gangrene, Pasteurella hemorrhagic septicemia, Lemierre syndrome, neonatal sepsis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00777257	PHASE4	COMPLETED	Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
NCT00539032	PHASE3	COMPLETED	Immunology and Safety of Menactra® in Children in Saudi Arabia
NCT00700713	PHASE2	COMPLETED	Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
NCT00771849	PHASE2	COMPLETED	Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
NCT00772070	PHASE2	COMPLETED	Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
NCT00772629	PHASE2	TERMINATED	Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
NCT00777790	PHASE2	COMPLETED	Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
NCT01133834	Not specified	COMPLETED	Correlation Between Cytokines and the Severity of Meningococcal Disease